Trevena Announces Poster Presentations at Recent Medical Meetings


CHESTERBROOK, PA — Trevena, Inc. (Nasdaq: TRVN) announced that three abstracts related to the Company’s commercial and clinical pipeline were presented at medical meetings in December. Each of the posters are available on the publications page of the Company’s website at

  • TRV045 Epilepsy Poster Title: TRV045, a Novel, Selective SIP Receptor Subtype-1 Modulator that Does Not Cause Lymphopenia is Efficacious in Acute and Chronic Rodent Epilepsy Models
    Summary of conclusions: Efficacy data from three nonclinical epilepsy models, in conjunction with evidence of an anti-inflammatory mechanism, suggest that selective modulation of S1P1 receptors by TRV045 may provide a new therapeutic option for the treatment of epilepsy.
  • OLINVYK Neurocognitive Poster Title: Oliceridine Demonstrates a Reduced Effect on Neurocognitive Function in Humans, Compared to Morphine: A Phase 1, Randomized, Placebo-Controlled, Dose-ranging, Partial Block, Cross-over Study
    Summary of conclusions: OLINVYK has a reduced impact on several clinically relevant measures of cognitive performance, compared to IV morphine, including measures of sedation, motor performance, and eye-hand coordination.
  • OLINVYK GI Poster Title: Gastrointestinal Adverse Effects Associated with the Use of Intravenous Oliceridine Compared to Intravenous Hydromorphone or Fentanyl in Acute Pain Management Utilizing Indirect Treatment Comparison Methods
    Summary of conclusions: When AEs were compared in an indirect treatment comparison (ITC) analysis using morphine as the common comparator, OLINVYK was found to significantly reduce the incidence of nausea and/or vomiting or the need for antiemetics in orthopedic surgical procedures compared to hydromorphone or fentanyl. Results in plastic surgery were not significantly different.

“We are pleased to advance the clinical understanding of the potential differentiated effect of OLINVYK versus traditional IV opioids. These data demonstrate that, compared to IV morphine, OLINVYK shows a statistically significant reduced impact on saccadic eye movement peak velocity, a sensitive measure of the sedating action of medications,” said Mark Demitrack, Senior Vice President and Chief Medical Officer of Trevena. “We are also excited by recent nonclinical results for our novel S1P1 receptor modulator, TRV045, which shows efficacy in three different acute and chronic animal models for epilepsy. We are encouraged by these data, given our recent announcement of positive topline results from our first-in-human Phase 1 study with TRV045.”

READ:  Cantaloupe, Inc. Appoints Anna Novoseletsky as Chief Legal and Compliance Officer & General Counsel, Corporate Secretary

For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News.

Thanks for visiting! Looking for some Chester County pride? We got you covered! Shop our MyChesCo store and show your love for Chester County, Pennsylvania. We got shirts, hats, and more – all with a unique ChesCo flair. Plus, proceeds from each purchase helps support our mission of bringing reliable information and resources to the people of Chester County.